In consultation: Guidance and quality standards
Showing 1 to 2 of 2
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |